Search for a trial

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dacetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial

The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in…

Microvascular Resistance Reserve And Myocardial Mass
A Prospective exploratory study

The primary objective of this study is to compare MRR measured at two locations in the LAD (proximal LAD and mid-LAD, i.e. distal to the first large diagonal branch) and to investigate if MRR remains unchanged with this change of myocardial mass.

A PROSPECTIVE MULTINATIONAL STUDY OF THE NATURAL HISTORY OF PARTICIPANTS WITH BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY

Primary:Determine baseline and changes over time in cardiac structure and function in BAG3 associated DCM.Secondary:Assess the progression of prognostic disease biochemical biomarkers in BAG3 associated DCM.

Seroprevalence Study of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV) in Patients with Plakophilin 2 (PKP2)-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

PrimaryInvestigate the seroprevalence of pre-existing antibodies to AAV in patients with PKP2-associated ARVCSecondaryTo characterize the burden of illness in patients with pathogenic or likely pathogenic PKP2 mutationsTo characterize arrhythmic…

International Consortium for Multimodality Phenotyping in Adults with Non-compaction

The ultimate goal of the consortium is to use state-of-the-art imaging, genetics, and machine-learning techniques to identify NCCM patients at risk for severe arrhythmia or stroke and guide preventive therapy using personalized risk scores

PROFID EHRA
PRevention Of sudden cardiac death aFter myocardial Infarction by Defibrillator im-
plantation

To demonstrate that in post-MI patients with symptomatic heart failure who receive optimal medical therapy (OMT) for this condition, and with reduced LVEF <=35%, OMT without implantable cardioverter defibrillator (ICD) implantation (index…